Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma

Background The establishment and progression of metastases remains the life‐limiting factor for dogs diagnosed with osteosarcoma (OS). The pattern of metastases is likely regulated through interactions between chemokine receptors and chemokines, and perturbations in these signaling cascades responsible for cytoskeletal organization and directional migration have the potential to alter metastatic cell trafficking behaviors. Hypothesis Zoledronate will impair directional migration of OS cells through downregulation of chemokine (C‐X‐C motif) receptor 4 (CXCR4) expression and functionality. Samples Nineteen archived tumor specimens and plasma from 20 dogs with OS. Methods Prospectively, the expressions of CXCR4 were studied in OS cell lines and spontaneous tumor samples. The effect of zoledronate on CXCR4 expression and functionality was investigated by characterizing responses in 3 OS cell lines. In 19 OS specimens and 20 dogs with OS, changes in CXCR4 expression and circulating CXCR4 concentrations were characterized in response to zoledronate therapy respectively. Results All canine OS cells express CXCR4, and zoledronate reduces CXCR4 expression and functionality by 27.7% (P < .0001), through augmented proteasome degradation and reduced prenylation of heterotrimeric G‐proteins in 33% of tumor cell lines evaluated. In OS‐bearing dogs, zoledronate reduces CXCR4 expressions by 40% within the primary tumor compared to untreated controls (P = .03) and also decreases the circulating concentrations of CXCR4 in 18 of 20 dogs with OS. Conclusions and clinical importance Zoledronate can alter CXCR4 expression and functionality in OS cells, and consequent perturbations in CXCR4 intracellular signaling cascades might influence patterns of metastases.

• Publication year

  2016

• Venue

  Journal of Veterinary Internal Medicine

• Publication date

  2016-06-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/jvim.14257PMID 27251585PMCID 5089657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma

  2017influential reference
• A novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR4

  2015cited by this paper
• Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis

  2014influential reference
• A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

  2014cited by this paper
• Comparison of Carboplatin and Doxorubicin‐Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma

  2014cited by this paper
• Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

  2014cited by this paper
• The intricate role of CXCR4 in cancer.

  2014influential reference
• Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents

  2012cited by this paper
• Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice

  2011cited by this paper
• Soluble chemokine receptor CXCR4 is present in human sera.

  2011cited by this paper
• Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases.

  2010cited by this paper
• How do bisphosphonates inhibit bone metastasis in vivo?

  2010cited by this paper
• Zoledronic acid protects against osteosarcoma‐induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model

  2010cited by this paper
• Cancer esearch oenvironment and Immunology s of Osteoclasts Contributes to Development of R eosarcoma Pulmonary Metastases

  2010cited by this paper
• Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.

  2009influential reference
• Zoledronic acid for the treatment of appendicular osteosarcoma in a dog.

  2009cited by this paper
• Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model

  2009cited by this paper
• Translating the Metastasis Paradigm from Scientific Theory to Clinical Oncology

  2009cited by this paper
• Biodistribution and Plasma Protein Binding of Zoledronic Acid

  2008cited by this paper
• Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells

  2008cited by this paper
• New insights on the role of CXCR4 in cancer metastasis

  2008cited by this paper
• Heterotrimeric G protein activation by G-protein-coupled receptors

  2008cited by this paper
• Investigating CXCR4 expression in canine appendicular osteosarcoma.

  2008cited by this paper
• Regulation of CXCR4 signaling.

  2007cited by this paper
• Assembly and trafficking of heterotrimeric G proteins.

  2007cited by this paper
• Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases

  2007influential reference
• THE EFFECT OF THE BISPHOSPHONATE ALENDRONATE ON VIABILITY OF CANINE OSTEOSARCOMA CELLS IN VITRO

  2004cited by this paper
• The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro

  2004cited by this paper
• New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects

  2003cited by this paper
• The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro.

  2003cited by this paper
• CXCR4/CCR5 Down-modulation and Chemotaxis Are Regulated by the Proteasome Pathway*

  2002cited by this paper
• Chemokines and the molecular basis of cancer metastasis.

  2001cited by this paper
• Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.

  2001cited by this paper
• Soluble receptors in human disease

  1998influential reference
• Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras

  1998cited by this paper
• The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.

  1997cited by this paper
• The role of prenylation in G-protein assembly and function.

  1996cited by this paper
• Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988).

  1992cited by this paper
• The distribution of secondary growths in cancer of the breast. 1889.

  1989cited by this paper
• 7 Canine Osteosarcoma: A Clinicopathologic Study of 194 Cases

  1969cited by this paper

• Gene expression profile comparison of primary and pulmonary metastatic lesions in a dog with appendicular osteosarcoma and hypertrophic osteopathy

  2024cites this paper
• Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma

  2023cites this paper
• Evaluation of the influence of the C-X-C motif chemokine ligand 12 / C-X-C chemokine receptor 4 axis on canine mammary gland tumor cell migration

  2023cites this paper
• Osteoid cell-derived chemokines drive bone-metastatic prostate cancer

  2023cites this paper
• Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study

  2022cites this paper
• Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy

  2021cites this paper
• Molecular Mechanisms of Canine Osteosarcoma Metastasis

  2021influential citation
• The Etiology of Cancer

  2020cites this paper
• Development of a novel immune-related genes prognostic signature for osteosarcoma

  2020cites this paper
• Clinical significance and in vitro cellular regulation of hypoxia mimicry on HIF-1α and downstream genes in canine appendicular osteosarcoma.

  2020cites this paper
• In vitro and in vivo characterization of stem‐like cells from canine osteosarcoma and assessment of drug sensitivity

  2018cites this paper
• Bisphosphonate conjugation for bone specific drug targeting

  2018cites this paper
• Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics

  2017cites this paper
• Tumors of the Skeletal System

  2012cites this paper
• and in vivo characterization of stem-like cells from canine vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity

  year unknowncites this paper